Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2019

01-10-2019 | Hepatitis C | Research Article

Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort

Authors: Miriam Coghlan, Aisling O’Leary, Gail Melanophy, Colm Bergin, Suzanne Norris

Published in: International Journal of Clinical Pharmacy | Issue 5/2019

Login to get access

Abstract

Background Medication reconciliation and drug–drug interaction management represent important patient safety processes completed by pharmacists as part of Hepatitis C patient care. Objectives To describe the pharmacist-led interventions of medication reconciliation and drug–drug interaction assessment, grading and management in a real-world Hepatitis C treatment cohort and to assesses the impact on patient outcomes. Setting Two Hepatitis C hospital outpatient clinics at St. James’s Hospital, Dublin. Method Patients treated with Hepatitis C direct acting anti-viral agents between December 2014 and February 2017 were included in this retrospective cohort study. The study employed a standardised medication reconciliation proforma and drug–drug interaction reference list. Main outcome measures Analyse medication variances identified during pharmacist-led medication reconciliation. Assess the prevalence, type and severity of drug–drug interactions between direct acting anti-virals and co-medications. Assess the rate of prescriber acceptance of the pharmacist-developed drug–drug interaction management strategies. Results Among the 300 patients in this study, medication reconciliation identified 1543 co-medications, with 71% of patients prescribed co-medications which were subject to a potential drug–drug interaction. Drug–drug interaction assessments assigned a rating of severe to 68 interaction episodes. At least one co-medication was stopped during treatment in 25% of patients to facilitate drug–drug interaction management. Pharmacist proposed management recommendations were accepted by prescribers in 96.9% of cases. The sustained virological response rate among the cohort was 92.7%. Conclusions In this Hepatitis C pre-treatment pharmacist assessment analysis, a significant number of medication reconciliation variances and clinically significant drug–drug interactions were identified which present unique and important patient safety risks. Pharmacist-led management strategies aided the achievement of optimum treatment response while promoting patient safety and antiviral stewardship.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380:2095–28.CrossRef Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380:2095–28.CrossRef
2.
go back to reference van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic Hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRef van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic Hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRef
3.
go back to reference Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic Hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–84.CrossRef Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic Hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–84.CrossRef
4.
go back to reference Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, et al. New Hepatitis C therapies for special patient populations. Expert Opin Pharmacother. 2016;17(2):217–29.CrossRef Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, et al. New Hepatitis C therapies for special patient populations. Expert Opin Pharmacother. 2016;17(2):217–29.CrossRef
6.
go back to reference Gray E, O’Leary A, Bergin C, Cannon M, Courtney G, Crosbie O, et al. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert Rev Gastroenterol Hepatol. 2017;11(6):593–601.CrossRef Gray E, O’Leary A, Bergin C, Cannon M, Courtney G, Crosbie O, et al. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert Rev Gastroenterol Hepatol. 2017;11(6):593–601.CrossRef
7.
go back to reference Honer Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug–drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561–7.CrossRef Honer Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug–drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561–7.CrossRef
8.
go back to reference Marra F, Leber W, Barclay ST, Christensen S, Ouzan D, Oules V, et al. High prevalence of co-morbidities and complex polypharmacy with drug–drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France. Hepatology. 2015;62:725A. Marra F, Leber W, Barclay ST, Christensen S, Ouzan D, Oules V, et al. High prevalence of co-morbidities and complex polypharmacy with drug–drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France. Hepatology. 2015;62:725A.
9.
go back to reference Maasoumy B, Zu Siederdissen CH, Marra F, Port K, Deterding K, Manns MP, et al. Prevalence of drug–drug interactions with modern interferon free antiviral regimens against Hepatitis C in a large real-world cohort. Hepatology. 2015;62:767A–8A. Maasoumy B, Zu Siederdissen CH, Marra F, Port K, Deterding K, Manns MP, et al. Prevalence of drug–drug interactions with modern interferon free antiviral regimens against Hepatitis C in a large real-world cohort. Hepatology. 2015;62:767A–8A.
10.
go back to reference Ottman AA, Townsend ML, Hashem MG, DiMondi VP, Britt RB. Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic Hepatitis C infection. Ann Pharmacother. 2018;52(8):763–8.CrossRef Ottman AA, Townsend ML, Hashem MG, DiMondi VP, Britt RB. Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic Hepatitis C infection. Ann Pharmacother. 2018;52(8):763–8.CrossRef
11.
go back to reference Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic Hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856–65.CrossRef Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic Hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856–65.CrossRef
12.
go back to reference Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing Hepatitis C virus treatment through pharmacist interventions: identification and management of drug–drug interactions. World J Gastroenterol. 2017;23(9):1618–26.CrossRef Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing Hepatitis C virus treatment through pharmacist interventions: identification and management of drug–drug interactions. World J Gastroenterol. 2017;23(9):1618–26.CrossRef
13.
go back to reference Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for Hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149(6):1315–7.CrossRef Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for Hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149(6):1315–7.CrossRef
14.
go back to reference Yeoh SW. Iatrogenic cushing syndrome from interaction between ritonavir and oral budesonide during direct acting antiviral Hepatitis C therapy. J Clin Exp Hepatol. 2016;6(3):246–9.CrossRef Yeoh SW. Iatrogenic cushing syndrome from interaction between ritonavir and oral budesonide during direct acting antiviral Hepatitis C therapy. J Clin Exp Hepatol. 2016;6(3):246–9.CrossRef
15.
go back to reference Rose AJ, Fischer SH, Paasche-Orlow MK. Beyond medication reconciliation: the correct medication list. JAMA. 2017;317(20):2057–8.CrossRef Rose AJ, Fischer SH, Paasche-Orlow MK. Beyond medication reconciliation: the correct medication list. JAMA. 2017;317(20):2057–8.CrossRef
16.
go back to reference Phillips M, Wilson JA, Aly A, Wood M, Poyah P, Drost S, et al. An evaluation of medication reconciliation in an outpatient nephrology clinic. Cannt J. 2016;26(2):29–33. Phillips M, Wilson JA, Aly A, Wood M, Poyah P, Drost S, et al. An evaluation of medication reconciliation in an outpatient nephrology clinic. Cannt J. 2016;26(2):29–33.
17.
go back to reference Galvin M, Jago-Byrne MC, Fitzsimons M, Grimes T. Clinical pharmacist’s contribution to medication reconciliation on admission to hospital in Ireland. Int J Clin Pharm. 2013;35(1):14–21.CrossRef Galvin M, Jago-Byrne MC, Fitzsimons M, Grimes T. Clinical pharmacist’s contribution to medication reconciliation on admission to hospital in Ireland. Int J Clin Pharm. 2013;35(1):14–21.CrossRef
18.
go back to reference Holland DM. Interdisciplinary collaboration in the provision of a pharmacist-led discharge medication reconciliation service at an Irish teaching hospital. Int J Clin Pharm. 2015;37(2):310–9.CrossRef Holland DM. Interdisciplinary collaboration in the provision of a pharmacist-led discharge medication reconciliation service at an Irish teaching hospital. Int J Clin Pharm. 2015;37(2):310–9.CrossRef
19.
go back to reference Mekonnen AB, McLachlan AJ, Brien JAE. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(2):128–44.CrossRef Mekonnen AB, McLachlan AJ, Brien JAE. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(2):128–44.CrossRef
20.
go back to reference Pevnick JM, Nguyen C, Jackevicius CA, Palmer KA, Shane R, Cook-Wiens G, et al. Improving admission medication reconciliation with pharmacists or pharmacy technicians in the emergency department: a randomised controlled trial. BMJ Qual Saf. 2018;27(7):512–20.CrossRef Pevnick JM, Nguyen C, Jackevicius CA, Palmer KA, Shane R, Cook-Wiens G, et al. Improving admission medication reconciliation with pharmacists or pharmacy technicians in the emergency department: a randomised controlled trial. BMJ Qual Saf. 2018;27(7):512–20.CrossRef
21.
go back to reference Milone AS, Philbrick AM, Harris IM, Fallert C. Medication reconciliation by clinical pharmacists in an outpatient family medicine clinic. J Am Pharm Assoc. 2014;54(2):181–7.CrossRef Milone AS, Philbrick AM, Harris IM, Fallert C. Medication reconciliation by clinical pharmacists in an outpatient family medicine clinic. J Am Pharm Assoc. 2014;54(2):181–7.CrossRef
22.
go back to reference Ashjian E, Salamin LB, Eschenburg K, Kraft S, Mackler E. Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. J Am Pharm Assoc. 2015;55(5):540–5.CrossRef Ashjian E, Salamin LB, Eschenburg K, Kraft S, Mackler E. Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. J Am Pharm Assoc. 2015;55(5):540–5.CrossRef
23.
go back to reference van der Gaag S, Janssen MJA, Wessemius H, Siegert CEH, Karapinar-Çarkit F. An evaluation of medication reconciliation at an outpatient Internal Medicines clinic. Eur J Intern Med. 2017;44:e32–4.CrossRef van der Gaag S, Janssen MJA, Wessemius H, Siegert CEH, Karapinar-Çarkit F. An evaluation of medication reconciliation at an outpatient Internal Medicines clinic. Eur J Intern Med. 2017;44:e32–4.CrossRef
24.
go back to reference Langness JA, Everson GT. Viral hepatitis: drug–drug interactions in HCV treatment–the good, the bad and the ugly. Nat Rev Gastroenterol Hepatol. 2016;13(4):194–5.CrossRef Langness JA, Everson GT. Viral hepatitis: drug–drug interactions in HCV treatment–the good, the bad and the ugly. Nat Rev Gastroenterol Hepatol. 2016;13(4):194–5.CrossRef
25.
go back to reference Macias J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/Hepatitis C virus-coinfected patients in clinical practice. HIV Med. 2017;18(7):445–51.CrossRef Macias J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/Hepatitis C virus-coinfected patients in clinical practice. HIV Med. 2017;18(7):445–51.CrossRef
26.
go back to reference Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, et al. Potential for drug–drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients. PLoS ONE. 2015;10(10):e0141164.CrossRef Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, et al. Potential for drug–drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients. PLoS ONE. 2015;10(10):e0141164.CrossRef
27.
go back to reference World Health Organisation. Guidelines for the screening, care and treatment of persons with chronic Hepatitis C infection. April 2014 World Health Organisation. Guidelines for the screening, care and treatment of persons with chronic Hepatitis C infection. April 2014
30.
go back to reference Micromedex Healthcare Series (database on CD-ROM) Version 5.1. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc, 2007 Micromedex Healthcare Series (database on CD-ROM) Version 5.1. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc, 2007
31.
go back to reference Stockley’s Drug Interactions 9th Edition, 2009, London: Pharmaceutical Press. Stockley’s Drug Interactions 9th Edition, 2009, London: Pharmaceutical Press.
32.
go back to reference Coghlan M, O'Leary A, Melanophy G, El Sherif O, Bergin C, Norris S. Hepatitis C direct-acting anti-viral treatment options in patients with epilepsy. A drug–drug interaction dilemma in Hepatitis C infection Posters. (Abstracts 1583). Hepatology. 2017;66(S1):149–1185.CrossRef Coghlan M, O'Leary A, Melanophy G, El Sherif O, Bergin C, Norris S. Hepatitis C direct-acting anti-viral treatment options in patients with epilepsy. A drug–drug interaction dilemma in Hepatitis C infection Posters. (Abstracts 1583). Hepatology. 2017;66(S1):149–1185.CrossRef
33.
go back to reference Moriarty F, Bennett K, Cahir C, Fahey T. Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in Ireland from 1997 to 2012. J Am Geriatr Soc. 2016;64(12):e291–6.CrossRef Moriarty F, Bennett K, Cahir C, Fahey T. Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in Ireland from 1997 to 2012. J Am Geriatr Soc. 2016;64(12):e291–6.CrossRef
34.
go back to reference Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug–drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55(5):605–13.CrossRef Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug–drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55(5):605–13.CrossRef
35.
go back to reference Kiser JJ. Clinically significant drug–drug interactions between Hepatitis C virus and HIV treatments. Top Antivir Med. 2016;24(3):106–10.PubMed Kiser JJ. Clinically significant drug–drug interactions between Hepatitis C virus and HIV treatments. Top Antivir Med. 2016;24(3):106–10.PubMed
36.
go back to reference Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care STDS. 2015;29(7):379–83.CrossRef Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care STDS. 2015;29(7):379–83.CrossRef
37.
go back to reference Rice DP, Jr., Faragon JJ, Banks S, Chirch LM. HIV/HCV antiviral drug interactions in the era of direct-acting antivirals. J Clin Transl Hepatol. 2016;4(3):234–40.CrossRef Rice DP, Jr., Faragon JJ, Banks S, Chirch LM. HIV/HCV antiviral drug interactions in the era of direct-acting antivirals. J Clin Transl Hepatol. 2016;4(3):234–40.CrossRef
38.
go back to reference Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, et al. Clinical management of drug–drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58(4):792–800.CrossRef Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, et al. Clinical management of drug–drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58(4):792–800.CrossRef
39.
go back to reference Pereira MT, Ferreira L, Horta AA, de Carvalho AC. Exogenous Cushing’s syndrome as a result of ritonavir–budesonide interaction—A case report. HIV AIDS Rev. 2016;15(2):91–3.CrossRef Pereira MT, Ferreira L, Horta AA, de Carvalho AC. Exogenous Cushing’s syndrome as a result of ritonavir–budesonide interaction—A case report. HIV AIDS Rev. 2016;15(2):91–3.CrossRef
40.
go back to reference Canalejo E, Pacheco MS. Cushing syndrome due to ritonavir–fluticasone interaction. CMAJ. 2012;184(15):1714.CrossRef Canalejo E, Pacheco MS. Cushing syndrome due to ritonavir–fluticasone interaction. CMAJ. 2012;184(15):1714.CrossRef
41.
go back to reference Sicras A, Ferrer V, Navarro R, Saez-Zafra M. SAT-116—Comorbidities, comedication and potential drug to drug interactions in chronic Hepatitis C patients: implications for adequate HCV treatment selection. J Hepatol. 2016;64(2):S747–8.CrossRef Sicras A, Ferrer V, Navarro R, Saez-Zafra M. SAT-116—Comorbidities, comedication and potential drug to drug interactions in chronic Hepatitis C patients: implications for adequate HCV treatment selection. J Hepatol. 2016;64(2):S747–8.CrossRef
42.
go back to reference European Association for the Study of the Liver. Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRef European Association for the Study of the Liver. Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRef
Metadata
Title
Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort
Authors
Miriam Coghlan
Aisling O’Leary
Gail Melanophy
Colm Bergin
Suzanne Norris
Publication date
01-10-2019
Publisher
Springer International Publishing
Keyword
Hepatitis C
Published in
International Journal of Clinical Pharmacy / Issue 5/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00876-6

Other articles of this Issue 5/2019

International Journal of Clinical Pharmacy 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.